Non-myeloablative stem cell transplant using 2-chlorodeoxyadenosine (2-CdA) in a patient with myelodysplastic syndrome (MDS)

T. Saito, S. Seo, R. Tanosaki, Y. Takaue, S. Mineishi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Non-myeloablative conditioning regimens for allogeneic stem cell transplant have become popular recently. With non-myeloablative conditioning, regimen-related toxicities (RRT) are mild and engraftment of allogeneic graft can be achieved consistently. We performed non-myeloablative allogeneic peripheral blood stem cell transplant using 2-chlorodeoxyadenosine (Cladribine; 2-CdA), busulfan, and anti-thymocyte globulin (ATG) for a patient with myelodysplastic syndrome (MDS). He also had hemochromatosis in the liver due to blood transfusions. His post-transplant clinical course was uncomplicated. Non-myeloablative conditioning regimen containing 2-CdA facilitates engraftment with minimal toxicity.

Original languageEnglish
Pages (from-to)88-90
Number of pages3
JournalExperimental Oncology
Volume22
Issue number1-2
Publication statusPublished - 2000 Mar 1
Externally publishedYes

Keywords

  • Cladribine
  • Myelodysplastic syndrome
  • Non-myeloablative stem cell transplant
  • Organ dysfunction

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Non-myeloablative stem cell transplant using 2-chlorodeoxyadenosine (2-CdA) in a patient with myelodysplastic syndrome (MDS)'. Together they form a unique fingerprint.

  • Cite this